Scott E. Eggener to Antineoplastic Agents
This is a "connection" page, showing publications Scott E. Eggener has written about Antineoplastic Agents.
Connection Strength
0.219
-
Lymph node count impacts survival following post-chemotherapy retroperitoneal lymphadenectomy for non-seminomatous testicular cancer: a population-based analysis. BJU Int. 2019 11; 124(5):792-800.
Score: 0.077
-
Management of Low-Stage Testicular Seminoma. Urol Clin North Am. 2015 Aug; 42(3):287-98.
Score: 0.059
-
Retroperitoneal lymph node dissection: reassessment of modified templates. BJU Int. 2009 Nov; 104(9 Pt B):1369-75.
Score: 0.040
-
Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol. 2008 May; 53(5):950-9.
Score: 0.035
-
Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol. 2007 Oct 01; 25(28):4365-9.
Score: 0.009